Effect of warfarin on plasma concentrations of vitamin K dependent coagulation factors in patients with stable control and monitored compliance.
There is a discrepancy in the results of reported studies of levels of vitamin K dependent coagulation factors in patients on warfarin therapy. This may have arisen partly because of the problem of assuring compliance with therapy in outpatients. The plasma concentrations of the vitamin K dependent clotting factors II, VII, IX and X were studied in 23 outpatients whose adherence to prescribed warfarin therapy was determined using a pharmacological indicator of compliance. In these patients, who were shown to have consistently good compliance and stable anticoagulant control over a period of 3-6 months, the activities in plasma of the four coagulation factors were not equally suppressed. Factor IX levels were significantly greater than those of factor VII (P less than 0.0001) which in turn were significantly greater than the levels of factor II (P less than 0.0001) or factor X (P less than 0.0001). There was no significant difference between the levels of factors II and X which were depressed to a similar extent. The proportion of variability of the International Normalized Ratio (INR) explained by linear regression was 51-77% and a model was derived to predict the INR from the mean of the levels of the four clotting factors. The concentrations of the coagulation factors II, VII, IX and X are likely to be highly dependent on the degree of compliance with warfarin therapy which should be taken into account when investigating the behaviour of these factors.
Kumar
S
S
University Department of Medicine, General Infirmary, Leeds.
Haigh
J R
JR
Tate
G
G
Boothby
M
M
Joanes
D N
DN
Davies
J A
JA
Roberts
B E
BE
Feely
M P
MP
D000368:Aged; D001779:Blood Coagulation Factors / Q000187:drug effects*; D005164:Factor IX / Q000187:drug effects; D005167:Factor VII / Q000187:drug effects; D005170:Factor X / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D010634:Phenobarbital; D011516:Prothrombin / Q000187:drug effects; D014859:Warfarin / Q000627:therapeutic use*
D001779:Blood Coagulation Factors; D014859:Warfarin; D005167:Factor VII; D011516:Prothrombin; D005164:Factor IX; D005170:Factor X; D010634:Phenobarbital